肠癌是最常见的消化系统恶性肿瘤之一，伊立替康（CPT-11）、氟尿嘧啶（5-FU）与亚叶酸联合的FOLFIRI方案为晚期结直肠癌患者的一线治疗化疗方案。晚期肠癌患者因肝功能异常常服用药食同源的五味子及其保肝药物。五味子类药物对CPT-11和5-FU在体内ADME过程相关的肠道菌群、代谢酶和转运体均存在相互作用。且作为肿瘤科临床药师，已发现临床FOLFIRI化疗患者的浓度和代谢产物的异常波动。因此，本课题首次从“肠道菌群-肠-肝”轴代谢调控角度出发，以整体化疗方案与五味子类保肝药的合理应用为切入点，研究保肝药对疾病化疗状态下，相关药物代谢酶、转运体和肠道菌群的影响，以及动物水平的药代动力学参数变化和ADR相关生化指标。在阐明临床FOLFIRI化疗方案与五味子类保肝药的合理性及可能存在的增效减毒协同抗肿瘤的基础上，为从轴代谢调控角度研究中药与西药的体内相互作用，提供新的解决思路与技术手段。

Colorectal cancer is the most common malignant neoplasm of digestive system, irinotecan, fluorouracil and leucovorin (FOLFIRI) has become the standard regimen as the first-line in treating advanced colorectal cancer. Patients with advanced or metastatic colorectal cancer are usually given liver-protective drugs such as Schisandra Chinensis because of liver dysfunction. The ADME presses of CPT-11 and 5-FU in vivo are all effect by intestinal flora、metabolic enzymes and transporter, which are also interaction with Schisandra Chinensis. Oncology clinical pharmacist found that the plasma concentration of chemotherapeutic drugs and its metabolite with abnormal fluctuation of patients received FOLFIRI chemotherapy regimen. The interactions studies between drugs of FOLFIRI chemotherapy regimen and Schisandra Chinensis with microbiota-gut-liver axis metabolic regulation will be developed. And the pharmacokinetic parameters and biochemical parameters will be counted to assure the secure use of combined medication. By above system experiments to prove that FOLFIRI chemotherapeutic drugs combined with Schisandra Chinensis may have better anti-tumor pharmacological action and efficacy enhancing and toxicity reducing and to provide a new research approach of herb-drug interaction mechanisms.